Patents by Inventor Satoshi Serada
Satoshi Serada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12222351Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.Type: GrantFiled: October 8, 2019Date of Patent: February 11, 2025Assignees: SEKISUI MEDICAL CO., LTD., NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITIONInventors: Shigeo Takayama, Tetsuji Naka, Satoshi Serada
-
Publication number: 20230250188Abstract: The present disclosure provides a humanized antibody that specifically binds to Glypican-1 (GPC-1), and also provides technologies, methods, medicines, and the like related to the humanized antibody. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has a high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells. In another aspect, the present disclosure also provides a composition for preventing or treating Glypican-1-positive cancer that includes a complex of a humanized anti-GPC-1 monoclonal antibody and a medicine having cytotoxic activity.Type: ApplicationFiled: June 10, 2021Publication date: August 10, 2023Applicant: NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITYInventors: Tetsuji Naka, Satoshi Serada
-
Publication number: 20220356265Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.Type: ApplicationFiled: June 22, 2022Publication date: November 10, 2022Applicants: Keio University, Iwate Medical UniversityInventors: Tomonori YAGUCHI, Kenji MORII, Yutaka KAWAKAMI, Daiki KATO, Tetsuji NAKA, Satoshi SERADA, Minoru FUJIMOTO
-
Patent number: 11370845Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.Type: GrantFiled: June 24, 2016Date of Patent: June 28, 2022Assignees: Keio University, NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITYInventors: Tomonori Yaguchi, Kenji Morii, Yutaka Kawakami, Daiki Kato, Tetsuji Naka, Satoshi Serada, Minoru Fujimoto
-
Publication number: 20220127314Abstract: An object is to provide a leucine-rich ?2 glycoprotein composition comprising leucine-rich ?2 glycoprotein and having excellent preservation stability. The object can be achieved by a leucine-rich ?2 glycoprotein composition comprising leucine-rich ?2 glycoprotein and having a pH of 7.0 to 9.3.Type: ApplicationFiled: October 8, 2019Publication date: April 28, 2022Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITIONInventors: Shigeo TAKAYAMA, Tetsuji NAKA, Satoshi SERADA
-
Publication number: 20210382041Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.Type: ApplicationFiled: October 8, 2019Publication date: December 9, 2021Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITIONInventors: Shigeo TAKAYAMA, Tetsuji NAKA, Satoshi SERADA
-
Publication number: 20210340275Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: ApplicationFiled: June 30, 2021Publication date: November 4, 2021Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Publication number: 20200308299Abstract: Provided is a novel anti-Glypican-1 antibody and a method for using the same. Provided is an anti-Glypican-1 antibody having an intracellular invasion activity which has never been observed in conventional anti-Glypican-1 antibodies. By taking advantage of the intracellular invasion activity of the antibody according to the present invention, the present invention is usable for various therapeutic purposes beyond the scope of the conventional assumption. Also provided is a composition for preventing or treating Glypican-1 positive cancer, said composition comprising a complex of a substance capable of binding to Glypican-1 (for example, an anti-Glypican-1 antibody) with a drug having a cytotoxic activity.Type: ApplicationFiled: April 27, 2018Publication date: October 1, 2020Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto
-
Publication number: 20190023781Abstract: According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.Type: ApplicationFiled: October 3, 2018Publication date: January 24, 2019Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Patent number: 10174111Abstract: According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.Type: GrantFiled: December 25, 2014Date of Patent: January 8, 2019Assignee: National University Corporation Kochi UniversityInventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Publication number: 20180362658Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: ApplicationFiled: August 14, 2018Publication date: December 20, 2018Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Patent number: 10077316Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: GrantFiled: December 25, 2014Date of Patent: September 18, 2018Assignee: National University Corporation, Kochi UniversityInventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Publication number: 20180230230Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.Type: ApplicationFiled: June 24, 2016Publication date: August 16, 2018Inventors: Tomonori Yaguchi, Kenji Morii, Yutaka Kawakami, Daiki Kato, Tetsuji Naka, Satoshi Serada, Minoru Fujimoto
-
Patent number: 9611475Abstract: Provided are a novel prophylactic and/or therapeutic drug for an inflammatory disease and a method for searching for the same. A prophylactic and/or therapeutic agent for an inflammatory disease that comprises a substance capable of inhibiting the expression or function of leucine rich alpha 2 glycoprotein (LRG). A method of screening for an anti-inflammatory substance using LRG or an LRG-expressing cell, wherein the inhibition of the expression or function of LRG is used as an index.Type: GrantFiled: April 11, 2014Date of Patent: April 4, 2017Assignee: National Institutes of Biomedical Innovation, Health and NutritionInventors: Tetsuji Naka, Minoru Fujimoto, Satoshi Serada
-
Publication number: 20170066836Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: ApplicationFiled: December 25, 2014Publication date: March 9, 2017Inventors: Tetsuji NAKA, Satoshi SERADA, Minoru FUJIMOTO, Masayoshi TOYOURA, Yuji SHOYA
-
Publication number: 20170051056Abstract: The present invention makes it possible to obtain a novel therapeutic drug for malignant tumors. Specifically, the present invention provides a therapeutic drug for malignant tumors, said drug including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody or an antigen-binding fragment thereof, or a functional equivalent thereof, or an LSR inhibitor such as a nucleic acid. Said inhibitor uses a therapeutic drug for malignant tumors, said drug including an anti-LSR antibody, or an antigen-binding fragment thereof or a functional equivalent thereof. The inhibitor may also be an LSR antagonist. The abovementioned therapeutic drug may be administered to patients in whom the onset of an LSR-positive malignant tumor is judged to have occurred.Type: ApplicationFiled: December 25, 2014Publication date: February 23, 2017Inventors: Tetsuji NAKA, Satoshi SERADA, Minoru FUJIMOTO, Masayoshi TOYOURA, Yuji SHOYA
-
Publication number: 20160083725Abstract: Provided are a novel prophylactic and/or therapeutic drug for an inflammatory disease and a method for searching for the same. A prophylactic and/or therapeutic agent for an inflammatory disease that comprises a substance capable of inhibiting the expression or function of leucine rich alpha 2 glycoprotein (LRG). A method of screening for an anti-inflammatory substance using LRG or an LRG-expressing cell, wherein the inhibition of the expression or function of LRG is used as an index.Type: ApplicationFiled: April 11, 2014Publication date: March 24, 2016Applicant: National Institute of Biomedical Innovation, Health and NutritionInventors: Tetsuji Naka, Minoru Fujimoto, Satoshi Serada